Developing drugs to treat diseases creates opportunities to simultaneously address the urgent unmet medical needs of patient populations and access new markets.

The challenging clinical trials landscape for drugs continues to achieve new efficiencies due, in part, to streamlined regulatory processes, decentralized clinical trials models and next-generation technologies, all supported by a flexible and evolving supply chain.